Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up
| Autor: | Laurence Venat-Bouvet, A Benyoub, Clavere P, Pascal Bonnier, Christiane Lejeune, Nicole Tubiana-Mathieu, L Piana, D J Adjadj, J. Martin, V Lebrun-Ly, D. Genet, Y. Aubard, P. Juin, J L Labourey |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Time Factors Cyclophosphamide medicine.medical_treatment Breast Neoplasms Inflammatory breast cancer Disease-Free Survival chemoradiotherapy Breast cancer Internal medicine Clinical Studies Antineoplastic Combined Chemotherapy Protocols Humans Medicine skin and connective tissue diseases breast conservation Aged Epirubicin business.industry Carcinoma Ductal Breast Remission Induction Induction chemotherapy Middle Aged medicine.disease Combined Modality Therapy Survival Rate Carcinoma Lobular Treatment Outcome Concomitant Vindesine Female Dose Fractionation Radiation Fluorouracil Cisplatin Menopause inflammatory breast cancer business Mastectomy Chemoradiotherapy Follow-Up Studies medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | The aim of this study was to evaluate with a long follow-up the efficacy of concomitant chemoradiotherapy in non-metastatic inflammatory breast cancer (IBC) and to evaluate the breast conservation rate. Between 1990 and 2000, 66 non-metastatic patients with IBC were treated with chemotherapy and concomitant irradiation. The induction chemotherapy consisted of epirubicine, cyclophosphamide and vindesine, in association with split-course bi-fractionated irradiation to a total dose of 65 Gy with concomitant cisplatin and 5-fluorouracil. Maintenance chemotherapy consisted of high-dose methotrexate and six cycles of epirubicine, cyclophosphamide and fluorouracil. Hormonal treatment was given if indicated. Mastectomy was not systemic. Among 65 evaluable patients, 57 (87.6%) achieved a complete clinical response and had a breast conservation. Only six loco regional relapses were noted in six patients with a delay of 20 months and with concomitant metastatic dissemination in four cases. Median disease-free survival (DFS) was 28 months. Median overall survival (OS) was 63 months and median follow-up was 55.5 months. Induction chemotherapy and concomitant irradiation is feasible in patients with IBC, permitting a breast conservation with a high rate of local control with an OS comparable to that of the best recent series. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|